Symbol Lookup

Tuesday November 25, 2014 4:38 PM ET. Data delayed 15 minutes.
9.39
0.01 (0.11%)
Bid/Lots
9.39/6
Ask/Lots
9.41/2
Open/Prev Close
9.40/9.38
Day Range
9.21-9.50
52-Week Range
7.53-23.25
Vol/Avg Daily Vol
102.4K/144.4K

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
Cara Therapeutics to Webcast Presentation at 26th Annual Piper Jaffray Healthcare Conference
37 minutes ago by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 26 Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 2:30 p.m. ET in New York City.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr....

Nov 11, 2014

Cara Therapeutics to Webcast Presentation at 2014 Stifel Healthcare Conference
4:01PM ET on Tuesday Nov 11, 2014 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014, at 2:25 p.m. ET in New York City.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr....

Nov 10, 2014

Cara Therapeutics Reports Third Quarter 2014 Financial Results
4:11PM ET on Monday Nov 10, 2014 by GlobeNewswire
Companies Mentioned: CARA

-- Reported positive top-line data from human abuse liability trial for I.V. CR845

-- Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015

-- Conference call today at 4:30 p.m. ET

-- Reported positive top-line data from human abuse liability trial for I.V. CR845

-- Phase 3 registration trials for I.V. CR845 expected to initiate in early 2015

-- Conference call today at 4:30 p.m. ET

Nov 3, 2014

Cara Therapeutics to Announce Third Quarter 2014 Financial Results on November 10, 2014
4:01PM ET on Monday Nov 03, 2014 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 10, 2014, at 4:30 p.m. ET to report third quarter 2014 financial results and provide a corporate update.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the...

Oct 29, 2014

Midday Update: Stocks Little Changed Ahead of FOMC Conclusion
12:31PM ET on Wednesday Oct 29, 2014 by Midnight Trader
Companies Mentioned: GDX, GLD, GY, SWI, ORB, STM, X, INVN, ARCP, FB, USO, SLV, CARA, UNG
12:31 PM EDT, 10/29/2014 (MT Newswires) -- Stocks were see-sawing between the plus and minus columns Wednesday, treading water ahead of the 2:00 p.m. ET conclusion of the Federal Open Market Committee meeting. After grinding higher in pre-market tra...
12:31 PM EDT, 10/29/2014 (MT Newswires) -- Stocks were see-sawing between the plus and minus columns Wednesday, treading water ahead of the 2:00 p.m. ET conclusion of the Federal Open Market Committee meeting. After grinding higher in pre-market ...
← Newer123Older →

Peers Headlines

Today

Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in December 2014
9 hours ago by Marketwire
Companies Mentioned: THLD

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 11:30 a...

Nov 20, 2014

ChemoCentryx Shares Up More Than 9% Following Orphan Drug Designation For CCX168
4:43PM ET on Thursday Nov 20, 2014 by Midnight Trader
Companies Mentioned: CCXI
04:43 PM EST, 11/20/2014 (MT Newswires) -- ChemoCentryx (CCXI) a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, said the U.S. Food and Drug Administration (FDA) has granted orphan-drug...
ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA
4:30PM ET on Thursday Nov 20, 2014 by GlobeNewswire
Companies Mentioned: CCXI

ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, reported today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...

Eagle Pharmaceuticals to Present at Piper Jaffray 2014 Healthcare Conference
10:00AM ET on Thursday Nov 20, 2014 by Business Wire
Companies Mentioned: EGRX

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Piper Jaffray 26t...

Nov 17, 2014

ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis Disease Activity, in Addition to Previously Shown Kidney Disease Improvements
8:42AM ET on Monday Nov 17, 2014 by GlobeNewswire
Companies Mentioned: CCXI

ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported additional data from a Phase II clinical trial (the CLEAR trial) with CCX168, an inh...

Sector Update: Health-Care Stocks Lower Pre-Bell
7:46AM ET on Monday Nov 17, 2014 by Midnight Trader
Companies Mentioned: INO, THLD, AZN
07:46 AM EST, 11/17/2014 (MT Newswires) -- Top Health-Care Stocks JNJ -0.26% PFE -1.85% ABT -0.09% MRK +0.30% AMGN -1.0% Health-care shares were generally lower in pre-market trade Monday. In health-care stocks news, Inovio Pharmaceuticals (INO) ...
Sector Update: Health Care
7:46AM ET on Monday Nov 17, 2014 by Midnight Trader
Companies Mentioned: INO, THLD, AZN
07:46 AM EST, 11/17/2014 (MT Newswires) -- Health-care shares were generally lower in pre-market trade Monday. In health-care stocks news, Inovio Pharmaceuticals (INO) said Monday that the company and Roche have terminated their collaboration, op...
Threshold Pharma Says Data Show Activity of TH-302 Plus Bevacizumab in Glioblastoma Patients
7:09AM ET on Monday Nov 17, 2014 by Midnight Trader
Companies Mentioned: THLD
07:09 AM EST, 11/17/2014 (MT Newswires) -- Threshold Pharmaceuticals (THLD) said interim data from a phase1/2 study of its TH-302 anticancer drug in combination with Bevacizumab showed that 65% of patients achieved stable disease or tumor shrinka...
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
7:00AM ET on Monday Nov 17, 2014 by Marketwire
Companies Mentioned: THLD

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin(R)) for the treatment...

Nov 13, 2014

Pfenex Reports Third Quarter 2014 Results and Provides Business Update
4:05PM ET on Thursday Nov 13, 2014 by PR Newswire
Companies Mentioned: PFNX

Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, today reported financial results for the third quarter ended ...

← Newer123Older →